A Review of Agitation in Mental Illness: Treatment Guidelines and Current Therapies
J Clin Psychiatry 2006;67(suppl 10):13-21
© Copyright 2017 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Background: Agitation is an important therapeutic target in the acute and/or emergent setting, as
well as for longer-term care of patients with psychiatric illness. Method: Select reviews and guidelines
published (from 2000 to 2006) on the treatment of agitation in various psychiatric disorders were
evaluated. Results: After maximizing the safety of all individuals in the presence of an acutely agitated
patient, initial therapy generally involves verbal de-escalation. Pharmacologic management of
acute agitation relies on typical antipsychotics, particularly haloperidol; benzodiazepines; and atypical
antipsychotics. The selection of a specific agent (or combination of agents) should be guided
by etiologic considerations, efficacy of the drug(s), side effects, potential drug interactions, and drug
formulation. Seclusion or restraints are treatments of last resort due to safety issues. Conclusion: Compared with conventional antipsychotics (e.g., haloperidol), preliminary evidence indicates that
atypical antipsychotics effectively reduce agitation, are better tolerated, and have fewer side effects.
After an acute episode, atypical agents also help ease the transition from intramuscular to oral medication
to promote ongoing treatment.